Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You should research Dr Pezzotti. He was a scientist that did several studies for Biomet before joining Sintx in 2015. Hes been integral in development and testing of Si3n4 as well as a consultant for a study testing Sintx Si3n4 femoral heads against Biomets E1 liner in 2016; a decade after the last time these two companies tested their femoral head and liners together. This is an example of strategic parntership where you share resources and Dr Pezzotti is a major resource. Even recently Knighted in Italy for his contributions.
Some of Dr. Pezzotti's Biomet research for Biomet:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174052660
========================================
Sintx 2016 10k
This quote indicates the results of testing of their femoral head with a strategic partner will be released in 2017.
Those results were released testing Sintx Femoral head against Biomet's E1 liners. Thus Zimmer Biomet, or any of its subsidiaries, is Sintx strategic partner in this testing.
I should add that the current Chairman, former CEO, was a member of Zimmers surgeon panel from 2002-2014+ (dont know when or if he ever stopped being part of Zimmers panel.
He joined Sintx clinical advisory panel end of 2005. That femoral head-liner study in 2007 would have occurred in 2006 just after Dr Bal joined Sintx, then Amedica. Almost as if Zimmer sent him to Amedica to help develop/give advice for testing hip/knee implants using...Biomet IP it seems. That move didnt make sense back then but obviously post merger it does.
Dr. Sonny Bal, MD
https://web.archive.org/web/20240316192627/https://hipandknee.com/wp-content/uploads/2014/04/Dr.-Bal-CV.pdf
The stock is heavily manipulated. There are some hedge funds that have been targeting the stock with a short and distort campaign for about 9 years now. I post about that on Sintx board if you want more info on that.
The stock is not a reflection of the IP however. In fact the better Sintx does, the worse the stock performs because of those funds, in part. Go figure.
Si3n4 is a material that Zimmer & Biomet have been working with for going on 20 years so this isnt just "biotech". Its specific to ZB. For instance:
2007 (ORS Annual Meeting Feb 11-14)
THERMAL CONDUCTIVITY OF FEMORAL BALL STRONGLY INFLUENCED UHMWPE WEAR IN A HIP SIMULATOR STUDY
Amedica became SinTx when it expanded from just ortho industry.
Quote Source:
http://c.eqcdn.com/_5c7526ae538a6086a4025ef13f5136d2/amedica/db/265/660/pdf/0278.pdf
I'm curious about anything pertaining to biotech. If you don't know the reason for the selloff, just say so.
Just curious why you're more interested in the stock than the IP in relation to Zimmer Biomet?
That has nothing to do with the companies IP. I was just showing you why Zimmer Biomet would want the IP. It can be used on just about any material currently being used in the ortho/dental markets to bring its benefits to those materials. ZTA, Metals, PEEk, Si3n4 can imbue those materials with antimicrobial properties as well as enhance their osseointegration. Something not mentioned in the PR was the fact that coatings should reduce metal ion release into the body like indicated in this previous PR.
Why is SINT down 20% today?
More reasons for Zimmer Biomet to want this IP.
https://ir.sintx.com/news-events/press-releases/detail/236/sintx-receives-notice-of-allowance-for-united-states-patent
ZBH acquires—(private)—AI-driven surgical-guidance company_for_undisclosed_price:
https://investor.zimmerbiomet.com/news-and-events/news/2024/08-07-2024-113056395
ZBH reports 2Q24 results:
https://investor.zimmerbiomet.com/news-and-events/news/2024/08-07-2024-113041683
2Q24 results
• Revenue of $1.94B, +6% YoY in constant currency (+4% YoY in US dollars).
• GAAP EPS of $1.18, up from $1.00 in 2Q23.
• Non-GAAP* EPS of $2.01, up from $1.82 in 2Q23.
Updated 2024 guidance
• YoY sales growth of 5-6% in constant currency, unchanged from the guidance given three months ago.
• A (1.0%) sales headwind from exchange rates due to a stronger US dollar than anticipated in the prior guidance. I.e. YoY sales growth in US dollars is now expected to be 4-5% rather than the prior guidance of 4.5-5.5%.
• Non-GAAP* EPS of $8.00-8.15 (up from the actual $7.55 in 2023), which is unchanged from the guidance given three months ago.
2024-2027 guidance from 5/29/24 Investor Day (#msg-174509651)
• YoY sales growth of 4-6% (excluding exchange rates), equal to or slightly higher than the overall med-device market.
• YoY growth of non-GAAP* EPS at least 1.5 times the YoY sales growth (i.e. at least 6-9%).
*Non-GAAP EPS excludes restructuring costs.
Read the study see if you think the material good as I do and can help liven up the ortho industry.
Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application
https://www.mdpi.com/2571-6131/4/2/16/htm
Which one?
Yep 1 material.
You last two posts speak of a material (singular), implying that there is one specific substance you have in mind. Is this true?
Because it can be imbued and coated on other implants, Zimmer, if it acquired the tech one day, could make a lot of money licensing it out to other ortho companies.
Not to mention the material would help Zimmer diversify its portfolio as it can be used outside of ortho.
A biomaterial that bring with it several benefits over current materials. For instance, biodegradable and thus instead of accumulating in the body tissue/organs the way metals and plastic do, can be excreted.
A material that not not only resists bacteria but kills it to help prevent implant infections.
A material thats osteointegrative that should improve bone integration to prevent implant rejection.
A material that can be imbued into PEEK or used as a coating for metals so it can enhance current materials already in use in ortho/dental.
The added benefits should allow companies to increase pricing over older tech.
Zimmers been aware of this material for sometime. It needs to step up its partnership and expand their R&D efforts around this material already.
Can you elaborate?
New ortho material could change that.
ZBH’s new real-estate venture:
https://finance.yahoo.com/news/zimmer-biomet-outlines-strategy-deliver-210200055.html
Once upon a time—(~15-20 yrs ago)—medical devices were a hot growth area. Now the sector is growing at barely more than the rate of US price inflation.
ZBH issues 2024-2027 guidance:
https://finance.yahoo.com/news/zimmer-biomet-outlines-strategy-deliver-210200055.html
ZBH reports 1Q24 results—reiterates 2024 guidance:
https://finance.yahoo.com/news/zimmer-biomet-announces-first-quarter-103000875.html
2024 guidance remains non-GAAP EPS of $8.00-8.15; constant-currency YoY revenue growth of 5-6%; and a negative 0.5% hit to YoY sales growth from exchange rates.
ZBH reports 4Q23 results—issues 2024 guidance:
https://investor.zimmerbiomet.com/~/media/Files/Z/ZimmerBiomet-IR/press-release/zimmer-biomet-press-release-q4-2023.pdf
2024 guidance for revenue growth is +5-6% YoY in constant currency and +4.5-5.5% in USD.
2024 non-GAAP EPS guidance is $8.00-8.15. At the current share price (~$123), the midpoint of the guidance range represents a forward EPS of ~15x.
Note: ZBH’s non-GAAP EPS excludes restructuring costs, which were $61.2M ($0.29/sh) in 4Q23. I object to this policy for companies such as ZBH who are in a restructuring mode continually.
Independent director bought $225K of stock on the open market last week:
https://www.sec.gov/Archives/edgar/data/1136869/000106299323020641/xslF345X05/form4.xml
Re: GLP-1 effect on med-device companies
ZBH’s new CEO concurs with the discussion in #msg-173002788; from the 3Q23 CC transcript:
https://finance.yahoo.com/news/zimmer-biomet-holdings-inc-nyse-224434890.html
ZBH reports 3Q23 results—reiterates 2023 non-GAAP-EPS guidance:
https://investor.zimmerbiomet.com/news-and-events/news/2023/11-07-2023-113117335
3Q23 revenue was $1.754 billion, +4.7% YoY in constant currency.
3Q23 GAAP EPS was $0.77, down from $0.92 in 3Q22.
3Q23 non-GAAP EPS (which excludes restructuring costs) was $1.65, up from $1.58 in 3Q22.
ZBH reiterated 2023 non-GAAP EPS guidance of $7.47-7.57, despite a larger than previously expected hit from foreign currency.
ZBH CEO will become CEO of 3M’s healthcare spinoff:
https://finance.yahoo.com/news/bryan-hanson-named-ceo-3ms-122300047.html
https://finance.yahoo.com/news/zimmer-biomet-announces-leadership-transition-122000860.html
ZBH reports 2Q23 results—shares fall despite raised 2023 guidance:
https://investor.zimmerbiomet.com/news-and-events/news/2023/08-01-2023-113054956
https://finance.yahoo.com/news/medical-device-maker-zimmer-biomet-122133634.html
Medical-device stocks (including ZBH) are strong today, while health-insurance stocks (e.g. HUM) are weak. Somebody apparently just realized that elective-procedure volumes are back to pre-pandemic levels and growing.
Actually, there is no scientific evidence to support the claim that titanium blood serum levels increase by 3.5fold within one year of implantation. While titanium is commonly used in medical implants due to its biocompatibility, there is no known mechanism by which titanium implants can directly influence blood serum levels.
Titanium implants are known to integrate with surrounding tissues through a process called osseointegration, where the bone fuses with the implant. This integration occurs on a structural level, facilitating the stability and longevity of the implant. However, it does not lead to a significant alteration in blood serum composition or titanium levels within the bloodstream.
It's important to approach such claims with a critical mindset and rely on scientific studies and empirical evidence. While titanium implants have proven benefits in terms of their mechanical properties and compatibility with the human body, attributing miraculous serum level increases to titanium implants is unsupported by scientific research.
Remember, it's always best to consult reliable scientific sources and experts in the field when evaluating medical claims to ensure accurate and evidence-based information.
Did you know titanium bloodserum levels increase 3.5fold, on average, within 1 year of implantation?
While it is true that there are articles discussing potential adverse reactions to titanium (Ti) or its corrosive by-products, it's important to consider the overall scientific consensus and the weight of the evidence.
While a small subset of individuals may experience hypersensitivity or allergic reactions to certain metals, including titanium, these cases are relatively rare. The vast majority of individuals tolerate titanium implants without any adverse reactions or complications. Titanium has been extensively used in medical and dental applications for many years due to its biocompatibility and corrosion resistance.
It is crucial to differentiate between potential rare reactions in specific individuals and the general safety and effectiveness of titanium implants. The scientific and medical communities have thoroughly studied the biocompatibility and safety of titanium and its alloys. These studies have consistently shown that titanium implants have a high success rate and low incidence of adverse reactions in the general population.
It is important to approach scientific research with critical thinking and consider the overall body of evidence. While individual studies may highlight specific cases or potential concerns, they should be weighed against the larger body of research and scientific consensus. It is always recommended to consult with qualified healthcare professionals who can provide personalized advice based on individual circumstances and medical history.
"There are many published articles supporting these views, but there is recent scientific evidence that Ti, or its corrosive by-products, may cause harmful reactions in humans. It is important for all medical and dental professionals to understand the implications, complexities, and all potential pathways of exposure to this metal"
While it is true that some patients may experience less severe immune reactions to titanium implants, it is important to note that titanium is widely recognized as a biocompatible material with a low incidence of allergic reactions. The majority of individuals tolerate titanium implants well without any adverse effects.
Allergic reactions to titanium are considered extremely rare, and when they do occur, they tend to be localized and mild. The immune response to titanium implants is generally minimal, as titanium forms a protective oxide layer on its surface that helps prevent corrosion and immune reactions.
It is also worth mentioning that the medical field has rigorous testing and screening protocols in place to identify potential allergies or sensitivities before implanting any medical devices, including titanium implants. These pre-implantation tests, such as patch testing and laboratory investigations, help to identify individuals who may have a higher risk of adverse reactions to certain materials.
While it is possible for some patients to develop delayed sensitivities or immune reactions to titanium implants over time, it is crucial to approach such claims with scientific evidence and peer-reviewed studies. Without robust research demonstrating a widespread problem of undetected titanium allergies leading to various health issues, it would be speculative to attribute unrelated symptoms solely to titanium implants.
If individuals have concerns about their implants or suspect an allergic reaction, it is recommended to consult with healthcare professionals who can conduct proper medical evaluations and provide appropriate advice based on individual circumstances.
What makes it worse is alot of patients are having less severe immune reactions to titanium and thus do not know or pursue it. Blaming the problem on something else.
While it is true that some individuals may develop sensitivities or allergic reactions to certain materials over time, such as titanium implants, it is essential to consider the available scientific evidence and expert opinions on the matter.
When it comes to titanium implants, such as those used in dental or orthopedic procedures, allergic reactions are extremely rare. Titanium is known for its biocompatibility, meaning it is generally well-tolerated by the human body and does not typically trigger immune responses or sensitivities. Titanium implants have been extensively used for many years with a high success rate and minimal adverse reactions reported.
Allergic reactions to titanium are considered uncommon, and when they do occur, they are often associated with pre-existing allergies to other metals, such as nickel or cobalt, which may be present as impurities in the titanium alloy. In such cases, it is crucial for patients to inform their healthcare providers about any known metal allergies before undergoing implant procedures.
Furthermore, thorough pre-implant testing and evaluation are typically conducted to identify potential sensitivities or allergies. This includes assessing a patient's medical history, conducting skin patch tests, and utilizing other diagnostic techniques to determine the suitability of titanium implants. These measures help to minimize the risk of adverse reactions and ensure the best possible outcome for patients.
It is important to rely on scientifically sound studies, expert opinions, and medical guidelines when evaluating the safety and potential risks associated with medical implants. While anecdotal reports and individual experiences can provide valuable insights, they should be interpreted with caution and considered in the context of broader scientific knowledge and consensus.
Not true. People are testing and show no initial response but after having the implant for months to years, patients are developing sensitivities.
The problem is you'll never know who is going to be sensitive and its a growing problem.
CAN DENTAL IMPLANTS REALLY CAUSE MIGRAINES? NO – HERE’S WHY
https://badiedental.com/can-dental-implants-really-cause-migraines-no-heres-why/#:~:text=When%20Van%20Dyke%20came%20forward,his%20doctors%20found%20nothing%20abnormal.
If you are missing one or more teeth, you’ve likely heard that a titanium dental implant is an effective and modern replacement option. But there’s been some talk in the media about dental implants causing migraine headaches, most notably in 2013 when entertainer Dick Van Dyke claimed he was experiencing migraine headaches related to his dental implants. But how much truth is there to this claim? Can dental implants cause migraines, or are Van Dyke’s symptoms the result of another problem? Here’s what you need to know.
How the Myth Started
When Van Dyke came forward with his migraine story, he said that his migraines had been ongoing for a period of seven years. After rigorous tests including an MRI and a spinal tap, his doctors found nothing abnormal. That’s when Van Dyke concluded his dental implants must be the problem, although his publicity rep says that the doctors’ tests were inconclusive. From there, major entertainment tabloids caught wind of the story – and changed the headlines just enough to make it sound as if a doctor had made the dental implant conclusion instead of Van Dyke.
What Does the Science Tell Us?
Currently, there is no scientific evidence to support the idea that dental implants cause migraines. Dr. Lawrence G. Falender is a Fellow of the American Association of Oral Surgeons and a faculty member of the Indiana University School of Dentistry. Dr. Falender says that in the 26 years that he’s been performing dental implant surgery, he has never come across a case of dental implants causing migraines. Meanwhile. Dr. David Edenbaum has a scientific rationale for why dental implants can’t cause migraines in healthy patients. Dr. Edenbaum, who has been named one of America’s top dentists nine times courtesy of the Consumer’s Research Council of America, says that dental implants are too short to cause migraines. To cause a migraine, a dental implant would need to extend into the mouth – but they’re always encased in the jawbone, so even an improperly placed dental implant couldn’t cause a migraine.
But what about Van Dyke’s story? If a dental implant is too short to cause a migraine, then why did Van Dyke start getting migraines after getting a dental implant?
As it turns out, there are two potential causes of ongoing migraines in dental implant patients. The MELISA Foundation, an organization dedicated to the study of metal allergies, says that migraines are a symptom of a metal allergy.Though metal allergies are rare (they affect only 2-4% of all patients, according to MELISA Diagnostics), a 2013 research paper found that a metal allergy would explain symptoms such as headaches, muscle pain, and indigestion. Dental implants are made of titanium and can cause symptoms – including migraines – in people with metal allergies. That means the cause of the migraine isn’t the dental implant itself, but rather, the allergic reaction to it.
It’s also possible that improperly installed dental implants can create a misaligned bite, which could result in migraines. Misaligned bite is a minor issue that can be fixed with a bite analysis and orthotic.
Are Dental Implants a Safe Tooth Replacement Option?
Modern dental implants have been around since the 1970s, and the surgery used to fix titanium to the jawbone has been around even longer. After 45 years of research, there still aren’t any studies showing a link between dental implants and migraines. The truth is that when they’re properly inserted, dental implants are quite safe.
Followers
|
8
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
153
|
Created
|
08/11/12
|
Type
|
Free
|
Moderators DewDiligence |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |